TY - JOUR
T1 - Beyond traditional morphological characterization of lung neuroendocrine neoplasms
T2 - In silico study of next-generation sequencing mutations analysis across the four world health organization defined groups
AU - Centonze, Giovanni
AU - Biganzoli, Davide
AU - Prinzi, Natalie
AU - Pusceddu, Sara
AU - Mangogna, Alessandro
AU - Tamborini, Elena
AU - Perrone, Federica
AU - Busico, Adele
AU - Lagano, Vincenzo
AU - Cattaneo, Laura
AU - Sozzi, Gabriella
AU - Roz, Luca
AU - Biganzoli, Elia
AU - Milione, Massimo
N1 - Funding Information:
Funding: The work was supported by the Italian Association for Cancer Research (Grant No. 12162: Special Program 5 × 1000). The funding agency had no role in the design of the study, in the collection, analysis, and interpretation of data and in writing the manuscript.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/10
Y1 - 2020/10
N2 - Lung neuroendocrine neoplasms (LNENs) represent a rare and heterogeneous population of lung tumors. LNENs incidence rate has increased dramatically over the past 30 years. The current World Health Organization LNENs classification (WHO 2015), distinguished four LNENs prognostic categories, according to their morphology, necrosis amount and mitotic count: typical carcinoid (TC), atypical-carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC). At present, due to their rarity and biological heterogeneity there is still no consensus on the best therapeutic approach. Next-generation-sequencing analysis showed that WHO 2015 LNENs classes, could be characterized also by specific molecular alterations: frequently mutated genes involving chromatin remodeling and generally characterized by low mutational burden (MB) are frequently detected in both TC and AC; otherwise, TP53 and RB1 tumor suppressor genes alterations and high MB are usually detected in LCNEC and SCLC. We provide an overview concerning gene mutations in each WHO 2015 LNENs class in order to report the current LNENs mutational status as potential tool to better understand their clinical outcome and to drive medical treatment.
AB - Lung neuroendocrine neoplasms (LNENs) represent a rare and heterogeneous population of lung tumors. LNENs incidence rate has increased dramatically over the past 30 years. The current World Health Organization LNENs classification (WHO 2015), distinguished four LNENs prognostic categories, according to their morphology, necrosis amount and mitotic count: typical carcinoid (TC), atypical-carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC). At present, due to their rarity and biological heterogeneity there is still no consensus on the best therapeutic approach. Next-generation-sequencing analysis showed that WHO 2015 LNENs classes, could be characterized also by specific molecular alterations: frequently mutated genes involving chromatin remodeling and generally characterized by low mutational burden (MB) are frequently detected in both TC and AC; otherwise, TP53 and RB1 tumor suppressor genes alterations and high MB are usually detected in LCNEC and SCLC. We provide an overview concerning gene mutations in each WHO 2015 LNENs class in order to report the current LNENs mutational status as potential tool to better understand their clinical outcome and to drive medical treatment.
KW - In silico analysis
KW - Lung cancer
KW - Lung neuroendocrine neoplasm
UR - http://www.scopus.com/inward/record.url?scp=85092739185&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092739185&partnerID=8YFLogxK
U2 - 10.3390/cancers12102753
DO - 10.3390/cancers12102753
M3 - Article
AN - SCOPUS:85092739185
VL - 12
SP - 1
EP - 16
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 10
M1 - 2753
ER -